PSNL
What one share of Personalis holds
Services – Medical Laboratories
Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection.
Personalis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.71 |
|---|---|
| Profit | −$1.10 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$1.03 |
| Cash and investments | $0.88 |
| Book value | $2.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $3.10 | −$7.78 | $1.70 | −$1.61 | — | −$30.50 |
| 2018 | $12.33 | −$6.49 | $2.56 | −$0.74 | — | −$34.48 |
| 2019 | $3.62 | −$1.39 | $0.47 | −$1.47 | — | $3.41 |
| 2020 | $2.29 | −$1.20 | $0.09 | −$1.34 | — | $4.99 |
| 2021 | $1.95 | −$1.49 | $0.25 | −$1.87 | — | $6.91 |
| 2022 | $1.42 | −$2.48 | $1.09 | −$2.63 | — | $4.67 |
| 2023 | $1.53 | −$2.25 | $0.23 | −$1.39 | — | $2.56 |
| 2024 | $1.43 | −$1.37 | $0.03 | −$0.79 | — | $2.38 |
| 2025 | $0.78 | −$0.91 | $0.05 | −$0.89 | — | $2.55 |